AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target ...

AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer ...

AngioDynamics received FDA 510(k) clearance for its NanoKnife system for prostate tissue ablation in intermediate-risk ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...

Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate tissue ablation received regulatory clearance. The stock jumped almost 35% to a high of $9.42 in early ...

Published in Nature Communications, a new study led by the University of Minnesota Medical School and Duke University found ...

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once ...

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.

His insurance agent told him he’d first have to be screened for prostate cancer, which would require him to provide a blood sample that would be tested for the presence of prostate-specific antigen.

Two Channel Islands men have spoken about their experiences with prostate cancer to encourage men to get tested early. Neil Laffoley and Ian Brown spoke as Guernsey and Jersey's health service ...